drugset / Trial / NCT04331730
A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD
RandomizedParallel-groupDouble-blindTreatment
Summary
This study will evaluate the efficacy and safety of AKST4290 in combination with aflibercept injections in subjects with newly diagnosed neovascular age-related macular degeneration (nAMD).
Timeline
- Start
- 2020-01-28
- Primary completion
- 2021-08-19
- Completion
- 2021-09-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LAZUCIRNON | Small molecule | 400 mg | Oral |
| Subject | LAZUCIRNON | Small molecule | 800 mg | Oral |
| Background | Aflibercept | Protein / enzyme biologic | — | Intravitreal |